Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -62.59 Million USD | 54.26% |
| 2022 | -136.84 Million USD | -176.4% |
| 2021 | 179.12 Million USD | 133.27% |
| 2020 | -538.36 Million USD | -2183.92% |
| 2019 | -23.57 Million USD | 34.15% |
| 2018 | -35.79 Million USD | 51.06% |
| 2017 | -73.14 Million USD | 8.82% |
| 2016 | -80.21 Million USD | 30.09% |
| 2015 | -114.74 Million USD | 15.4% |
| 2014 | -135.63 Million USD | -106.17% |
| 2013 | -65.78 Million USD | 2.27% |
| 2012 | -67.32 Million USD | -105.06% |
| 2011 | -32.83 Million USD | -19.96% |
| 2010 | -27.36 Million USD | -8.3% |
| 2009 | -25.27 Million USD | -13.17% |
| 2008 | -22.33 Million USD | -5.05% |
| 2007 | -21.25 Million USD | -1423.8% |
| 2006 | -1.39 Million USD | 85.96% |
| 2005 | -9.93 Million USD | -16.8% |
| 2004 | -8.5 Million USD | -47.91% |
| 2003 | -5.75 Million USD | 55.08% |
| 2002 | -12.8 Million USD | -17.04% |
| 2001 | -10.93 Million USD | 14.39% |
| 2000 | -12.77 Million USD | -127.79% |
| 1999 | -5.61 Million USD | -18.86% |
| 1998 | -4.72 Million USD | -84.38% |
| 1997 | -2.56 Million USD | -108.13% |
| 1996 | -1.23 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -18.31 Million USD | 3.21% |
| 2024 Q2 | -17.86 Million USD | 2.42% |
| 2023 Q2 | -14.44 Million USD | -48.0% |
| 2023 FY | -62.59 Million USD | 54.26% |
| 2023 Q1 | -9.76 Million USD | 73.78% |
| 2023 Q4 | -18.91 Million USD | 0.94% |
| 2023 Q3 | -19.09 Million USD | -32.19% |
| 2022 Q4 | -37.23 Million USD | 23.35% |
| 2022 Q1 | -14.23 Million USD | -110.68% |
| 2022 FY | -136.84 Million USD | -176.4% |
| 2022 Q3 | -48.57 Million USD | -63.73% |
| 2022 Q2 | -29.66 Million USD | -108.36% |
| 2021 Q3 | 45.51 Million USD | 932.18% |
| 2021 Q4 | 133.32 Million USD | 192.89% |
| 2021 Q1 | -4.12 Million USD | 98.53% |
| 2021 Q2 | 4.41 Million USD | 206.96% |
| 2021 FY | 179.12 Million USD | 133.27% |
| 2020 FY | -538.36 Million USD | -2183.92% |
| 2020 Q3 | -194.09 Million USD | -234.93% |
| 2020 Q2 | -57.95 Million USD | -2306.85% |
| 2020 Q1 | 2.62 Million USD | -60.65% |
| 2020 Q4 | -280.29 Million USD | -44.41% |
| 2019 Q2 | 219 Thousand USD | 101.05% |
| 2019 FY | -23.57 Million USD | 34.15% |
| 2019 Q4 | 6.67 Million USD | 206.9% |
| 2019 Q3 | -6.24 Million USD | -2950.23% |
| 2019 Q1 | -20.94 Million USD | -270.73% |
| 2018 FY | -35.79 Million USD | 51.06% |
| 2018 Q1 | -21.54 Million USD | 20.2% |
| 2018 Q2 | -21.17 Million USD | 1.71% |
| 2018 Q3 | 12.57 Million USD | 159.39% |
| 2018 Q4 | -5.65 Million USD | -144.92% |
| 2017 Q3 | -23.27 Million USD | -126.97% |
| 2017 FY | -73.14 Million USD | 8.82% |
| 2017 Q4 | -26.99 Million USD | -16.02% |
| 2017 Q2 | -10.25 Million USD | 18.76% |
| 2017 Q1 | -12.62 Million USD | 58.9% |
| 2016 Q3 | -29.22 Million USD | -106.19% |
| 2016 Q1 | -6.1 Million USD | 74.64% |
| 2016 Q4 | -30.7 Million USD | -5.06% |
| 2016 Q2 | -14.17 Million USD | -132.15% |
| 2016 FY | -80.21 Million USD | 30.09% |
| 2015 Q1 | -46.43 Million USD | -8.78% |
| 2015 FY | -114.74 Million USD | 15.4% |
| 2015 Q3 | 22.61 Million USD | 133.83% |
| 2015 Q4 | -24.07 Million USD | -206.47% |
| 2015 Q2 | -66.84 Million USD | -43.96% |
| 2014 Q2 | -25.86 Million USD | 43.82% |
| 2014 Q3 | -21.04 Million USD | 18.64% |
| 2014 Q4 | -42.68 Million USD | -102.85% |
| 2014 Q1 | -46.04 Million USD | -172.58% |
| 2014 FY | -135.63 Million USD | -106.17% |
| 2013 Q3 | -22.91 Million USD | -97.6% |
| 2013 Q1 | -14.39 Million USD | 52.84% |
| 2013 FY | -65.78 Million USD | 2.27% |
| 2013 Q4 | -16.89 Million USD | 26.27% |
| 2013 Q2 | -11.59 Million USD | 19.45% |
| 2012 Q3 | -16.49 Million USD | -62.51% |
| 2012 Q1 | -10.15 Million USD | 19.28% |
| 2012 FY | -67.32 Million USD | -105.06% |
| 2012 Q4 | -30.52 Million USD | -85.04% |
| 2012 Q2 | -10.15 Million USD | 0.01% |
| 2011 Q2 | -12.32 Million USD | -46.62% |
| 2011 FY | -32.83 Million USD | -19.96% |
| 2011 Q4 | -12.57 Million USD | -2709.13% |
| 2011 Q3 | 482 Thousand USD | 103.91% |
| 2011 Q1 | -8.4 Million USD | 8.15% |
| 2010 Q1 | -5.84 Million USD | -34.09% |
| 2010 Q2 | -8.72 Million USD | -49.31% |
| 2010 Q3 | -3.64 Million USD | 58.27% |
| 2010 FY | -27.36 Million USD | -8.3% |
| 2010 Q4 | -9.15 Million USD | -151.35% |
| 2009 Q2 | -4.09 Million USD | 10.51% |
| 2009 Q3 | -12.24 Million USD | -198.93% |
| 2009 Q4 | -4.35 Million USD | 64.39% |
| 2009 FY | -25.27 Million USD | -13.17% |
| 2009 Q1 | -4.57 Million USD | 12.71% |
| 2008 Q3 | -5.41 Million USD | 10.51% |
| 2008 Q2 | -6.05 Million USD | -7.56% |
| 2008 Q1 | -5.62 Million USD | 24.41% |
| 2008 Q4 | -5.24 Million USD | 3.18% |
| 2008 FY | -22.33 Million USD | -5.05% |
| 2007 Q1 | -1.95 Million USD | 5.1% |
| 2007 Q3 | -3.9 Million USD | 50.86% |
| 2007 FY | -21.25 Million USD | -1423.8% |
| 2007 Q2 | -7.95 Million USD | -307.53% |
| 2007 Q4 | -7.44 Million USD | -90.36% |
| 2006 Q4 | -2.05 Million USD | -13.71% |
| 2006 Q1 | -3.95 Million USD | -99.19% |
| 2006 Q3 | -1.8 Million USD | -128.14% |
| 2006 FY | -1.39 Million USD | 85.96% |
| 2006 Q2 | 6.42 Million USD | 262.41% |
| 2005 FY | -9.93 Million USD | -16.8% |
| 2005 Q4 | -1.98 Million USD | 28.58% |
| 2005 Q3 | -2.78 Million USD | -5.46% |
| 2005 Q2 | -2.63 Million USD | -4.43% |
| 2005 Q1 | -2.52 Million USD | 42.49% |
| 2004 FY | -8.5 Million USD | -47.91% |
| 2004 Q4 | -4.39 Million USD | -93.82% |
| 2004 Q3 | -2.26 Million USD | -122.37% |
| 2004 Q2 | -1.01 Million USD | -23.07% |
| 2004 Q1 | -828 Thousand USD | 5.05% |
| 2003 Q1 | -1.59 Million USD | 7.93% |
| 2003 FY | -5.75 Million USD | 55.08% |
| 2003 Q4 | -872 Thousand USD | 26.54% |
| 2003 Q3 | -1.18 Million USD | 43.53% |
| 2003 Q2 | -2.1 Million USD | -32.12% |
| 2002 Q3 | -3.5 Million USD | 21.27% |
| 2002 Q1 | -3.12 Million USD | 9.26% |
| 2002 FY | -12.8 Million USD | -17.04% |
| 2002 Q4 | -1.72 Million USD | 50.64% |
| 2002 Q2 | -4.44 Million USD | -42.18% |
| 2001 Q4 | -3.44 Million USD | -37.99% |
| 2001 FY | -10.93 Million USD | 14.39% |
| 2001 Q3 | -2.49 Million USD | 0.0% |
| 2001 Q1 | -2.49 Million USD | 44.49% |
| 2001 Q2 | -2.49 Million USD | 0.0% |
| 2000 Q4 | -4.5 Million USD | -19.68% |
| 2000 FY | -12.77 Million USD | -127.79% |
| 2000 Q3 | -3.76 Million USD | 0.0% |
| 1999 FY | -5.61 Million USD | -18.86% |
| 1998 FY | -4.72 Million USD | -84.38% |
| 1997 FY | -2.56 Million USD | -108.13% |
| 1996 FY | -1.23 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4587.55% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -796.47% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 218.158% |
| Nascent Biotech, Inc. | -2.08 Million USD | -2898.493% |
| Rebus Holdings, Inc. | -1.02 Million USD | -6037.157% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 196.11% |
| Qrons Inc. | -789.34 Thousand USD | -7830.479% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9798.531% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -14966.706% |
| Skye Bioscience, Inc. | -37.64 Million USD | -66.289% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 16.493% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -851.915% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -22796.321% |
| SQZ Biotechnologies Company | -79.46 Million USD | 21.223% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -2064.263% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -3338.508% |
| Mesoblast Limited | -87.95 Million USD | 28.829% |
| Marizyme, Inc. | -65.34 Million USD | 4.205% |
| Genus plc | 7.9 Million USD | 892.392% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -474.738% |
| Pharming Group N.V. | -10.54 Million USD | -493.468% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2784.994% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1587.198% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -607.813% |
| ContraFect Corporation | -65.15 Million USD | 3.92% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1181.175% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -3523.77% |
| IMV Inc. | -36.48 Million USD | -71.571% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -676.693% |
| MultiCell Technologies, Inc. | -380.07 USD | -16470287.034% |
| ONE Bio Corp. | 8.67 Million USD | 821.468% |
| Accustem Sciences Inc. | -3.74 Million USD | -1570.902% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -21.1% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -4840.204% |
| Q BioMed Inc. | -2.05 Million USD | -2950.495% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1576.909% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -2529.249% |
| Biomind Labs Inc. | -1.21 Million USD | -5055.07% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -4.811% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1918.172% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -692.082% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -3111.442% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -417895.459% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -294.413% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -976.092% |
| GB Sciences, Inc. | -1.36 Million USD | -4497.199% |
| Alpha Cognition Inc. | -13.77 Million USD | -354.519% |
| HST Global, Inc. | -146.21 Thousand USD | -42714.445% |
| CSL Limited | 2.64 Billion USD | 102.369% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -3467.36% |
| Halberd Corporation | -79.67 Thousand USD | -78466.946% |
| Enzolytics Inc. | -2.17 Million USD | -2775.693% |
| Agentix Corp. | -1.37 Million USD | -4455.268% |
| Resverlogix Corp. | -3.61 Million USD | -1634.044% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1873.838% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 78.784% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 63976.531% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1004.01% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1475.613% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1968.612% |
| AVAX Technologies, Inc. | -6.41 Million USD | -876.028% |
| Zenith Capital Corp. | -10.59 Million USD | -490.78% |
| Genscript Biotech Corporation | -95.47 Million USD | 34.436% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -269235.685% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1409.888% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -103471.092% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -3021.966% |
| Kadimastem Ltd | -3.3 Million USD | -1792.696% |
| Helix BioMedix, Inc. | -1.05 Million USD | -5827.616% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -1539.146% |
| BioStem Technologies, Inc. | -8.48 Million USD | -637.936% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -14082.917% |
| LadRx Corporation | 400.44 Thousand USD | 15732.437% |
| Cell Source, Inc. | -5.32 Million USD | -1076.405% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6216.122% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6216.122% |
| NovAccess Global Inc. | -4.76 Million USD | -1212.572% |
| Affymax, Inc. | -14.42 Million USD | -333.992% |
| Itoco Inc. | -1.86 Million USD | -3249.34% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1309.083% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -3650.689% |
| Mobile Lads Corp. | -2.26 Million USD | -2665.838% |
| CytoDyn Inc. | -49.84 Million USD | -25.597% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -79106.154% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -27340.417% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -6548.653% |
| SYBLEU INC | -180.3 Thousand USD | -34618.586% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -3781.538% |
| International Stem Cell Corporation | -131 Thousand USD | -47685.496% |
| Bioxytran, Inc. | -4.28 Million USD | -1362.593% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -115243.087% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -2374.027% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -30.219% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2861.164% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -7916.397% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1875.979% |
| Neutra Corp. | -233.46 Thousand USD | -26713.013% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -208.506% |
| PureTech Health plc | -65.69 Million USD | 4.716% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -194.354% |
| IXICO plc | -1.17 Million USD | -5214.007% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -530.593% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -9.577% |
| CSL Limited | 2.64 Billion USD | 102.369% |
| Cellectis S.A. | -103.17 Million USD | 39.327% |